Spots Global Cancer Trial Database for sarcoma, soft tissue
Every month we try and update this database with for sarcoma, soft tissue cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS) | NCT00204646 | Sarcoma, Soft T... | Adriamycin Ifosfamide Etoposide Carboplatin | 18 Years - 65 Years | University Hospital Tuebingen | |
| Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients | NCT03985722 | Sarcoma, Soft T... | Olaratumab and ... | 18 Years - 80 Years | Grupo Espanol de Investigacion en Sarcomas | |
| Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment | NCT02812654 | Sarcoma, Soft T... | Doxorubicin Ifosfamide radiotherapy | 18 Years - 75 Years | AC Camargo Cancer Center | |
| Transcutaneous Oxygen as a Predictor of Wound Healing Complications in Preoperatively Radiated Soft Tissue Sarcoma | NCT02897128 | Sarcoma, Soft T... | Observational O... | 18 Years - | The Cleveland Clinic | |
| Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients | NCT03985722 | Sarcoma, Soft T... | Olaratumab and ... | 18 Years - 80 Years | Grupo Espanol de Investigacion en Sarcomas | |
| Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma | NCT00297258 | Sarcoma, Soft T... | pazopanib | 21 Years - | GlaxoSmithKline | |
| Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy | NCT02300545 | Sarcoma, Soft T... Soft Tissue Sar... | Pazopanib | 18 Years - | Washington University School of Medicine | |
| Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS | NCT01995981 | Sarcoma, Soft T... | Pazopanib | 18 Years - | Radboud University Medical Center | |
| Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma | NCT05488366 | Sarcoma, Soft T... | Pembrolizumab Radiation thera... | 18 Years - | University of California, Irvine | |
| Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma | NCT02808247 | Sarcoma, Soft T... | Nintedanib Ifosfamide | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma | NCT00142571 | Sarcoma, Soft T... | Gemcitabine Docetaxel | 10 Years - | Memorial Sloan Kettering Cancer Center | |
| Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy | NCT00753688 | Sarcoma, Soft T... | PAZOPANIB Placebo | 18 Years - | GlaxoSmithKline | |
| Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma | NCT00189137 | Sarcoma, Soft T... | ifosfamide and ... | 10 Years - | University of Michigan Rogel Cancer Center | |
| Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients | NCT03985722 | Sarcoma, Soft T... | Olaratumab and ... | 18 Years - 80 Years | Grupo Espanol de Investigacion en Sarcomas | |
| Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS | NCT01995981 | Sarcoma, Soft T... | Pazopanib | 18 Years - | Radboud University Medical Center | |
| A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma | NCT05886634 | Dedifferentiate... Soft Tissue Sar... Sarcoma,Soft Ti... Sarcoma Recurrent Dedif... Unresectable De... Metastatic Dedi... | Etrumadenant Zimberelimab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma | NCT05138146 | Sarcoma, Soft T... | 609A doxorubicin hyd... | 18 Years - | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | |
| Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment | NCT02812654 | Sarcoma, Soft T... | Doxorubicin Ifosfamide radiotherapy | 18 Years - 75 Years | AC Camargo Cancer Center | |
| A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma | NCT05886634 | Dedifferentiate... Soft Tissue Sar... Sarcoma,Soft Ti... Sarcoma Recurrent Dedif... Unresectable De... Metastatic Dedi... | Etrumadenant Zimberelimab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Long Term Morbidity and Quality of Life in Retroperitoneal Sarcomas | NCT03480399 | Sarcoma, Soft T... Retroperitoneal... Surgery Quality of Life Morbidity | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | ||
| a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4 | NCT00130858 | Sarcoma, Soft T... | Topotecan Carboplatin | - 21 Years | Cooperative Weichteilsarkom Study Group | |
| BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas | NCT00406601 | Sarcoma, Soft T... | Sorafenib (BAY-... | 18 Years - | Istituto Clinico Humanitas | |
| Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients | NCT02275286 | Liposarcoma, My... Sarcoma, Soft T... Leiomyosarcoma Liposarcoma Pleomorphic Lip... | Trabectedin Radiotherapy | 18 Years - | Grupo Espanol de Investigacion en Sarcomas | |
| Alimta Plus Gemcitabine for Advanced Sarcoma | NCT00860015 | Sarcoma, Soft T... | Alimta Gemcitabine | 18 Years - | Columbia University | |
| Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients | NCT02275286 | Liposarcoma, My... Sarcoma, Soft T... Leiomyosarcoma Liposarcoma Pleomorphic Lip... | Trabectedin Radiotherapy | 18 Years - | Grupo Espanol de Investigacion en Sarcomas | |
| Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia | NCT01491594 | Sarcoma, Soft T... Osteosarcoma Neoplasms, Conn... | Eltrombopag | 18 Years - 82 Years | Duke University | |
| Alimta Plus Gemcitabine for Advanced Sarcoma | NCT00860015 | Sarcoma, Soft T... | Alimta Gemcitabine | 18 Years - | Columbia University | |
| Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma | NCT02367651 | Sarcoma, Soft T... | Pazopanib 800 m... Placebo | 18 Years - | GlaxoSmithKline | |
| Trabectedin Maintenance Post 1st-line in STS | NCT02929394 | Sarcoma, Soft T... | Trabectedin | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Swiss Sarcoma Network: Prediction Model for Patient Selection in Sarcoma Care | NCT04300257 | Sarcoma | - | Kantonsspital Winterthur KSW | ||
| A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma | NCT00490451 | Sarcoma, Soft T... | LY573636-sodium | 18 Years - | Eli Lilly and Company | |
| Evaluation of Adaptive Radiation Therapy in Pre-operative or Exclusive Radiation Therapy for Limb Soft Tissues Sarcomas | NCT03680430 | Sarcoma, Soft T... | Adaptive radiat... | 18 Years - | Institut Paoli-Calmettes | |
| A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas | NCT03058406 | Sarcoma, Soft T... | Eribulin mesyla... | - | Eisai Inc. | |
| Metabolic Characteristics of Sarcoma In Vivo Using HP 13-C Magnetic Resonance Spectroscopic Imaging (MRSI) | NCT03759704 | Sarcoma, Soft T... | Hyperpolarized ... | 18 Years - 100 Years | University of Texas Southwestern Medical Center | |
| Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma | NCT06114173 | Sarcoma, Soft T... | Cardunilizumab | 18 Years - 75 Years | Xiangya Hospital of Central South University | |
| Long Term Neurotoxic Effects of Chemotherapy in Survivors of Bone and Soft Tissue Sarcomas. A Retrospective Study | NCT02309242 | Sarcoma, Soft T... Osteosarcoma Tu... | Neuropsychologi... | 7 Years - 25 Years | Universitaire Ziekenhuizen KU Leuven | |
| TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients | NCT00289809 | Sarcoma, Soft T... | combination of ... | 18 Years - | Istituto Clinico Humanitas | |
| A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas | NCT03058406 | Sarcoma, Soft T... | Eribulin mesyla... | - | Eisai Inc. | |
| A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma | NCT02326025 | Sarcoma, Soft T... | Olaratumab Doxorubicin | 18 Years - | Eli Lilly and Company | |
| Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS | NCT01995981 | Sarcoma, Soft T... | Pazopanib | 18 Years - | Radboud University Medical Center | |
| Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS) | NCT00204620 | Sarcoma, Soft T... | Bendamustin | 18 Years - | University Hospital Tuebingen | |
| Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia | NCT01491594 | Sarcoma, Soft T... Osteosarcoma Neoplasms, Conn... | Eltrombopag | 18 Years - 82 Years | Duke University | |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | NCT02584309 | Sarcoma, Soft T... Soft Tissue Sar... Undifferentiate... Leiomyosarcoma Liposarcoma Synovial Sarcom... Myxofibrosarcom... Angiosarcoma Fibrosarcoma Malignant Perip... Epithelioid Sar... | Dexrazoxane Doxorubicin | 18 Years - | Washington University School of Medicine | |
| Efficacy and Safety Evaluation of Pegamotecan (PEG-camptothecin) in Advanced or Metastatic Soft Tissue Sarcoma | NCT00079950 | Sarcoma, Soft T... | Pegamotecan | 18 Years - | Enzon Pharmaceuticals, Inc. | |
| Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma | NCT05488366 | Sarcoma, Soft T... | Pembrolizumab Radiation thera... | 18 Years - | University of California, Irvine | |
| BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas | NCT00406601 | Sarcoma, Soft T... | Sorafenib (BAY-... | 18 Years - | Istituto Clinico Humanitas | |
| Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis | NCT00243685 | Breast Neoplasm... Lung Neoplasms Ovarian Neoplas... Sarcoma, Soft T... | Laboratory Assa... Mick Assay | 18 Years - 85 Years | Pierian Biosciences | |
| A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma | NCT05138146 | Sarcoma, Soft T... | 609A doxorubicin hyd... | 18 Years - | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | |
| BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas | NCT00406601 | Sarcoma, Soft T... | Sorafenib (BAY-... | 18 Years - | Istituto Clinico Humanitas | |
| Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery | NCT02464332 | Sarcoma, Soft T... | BLZ-100 | 18 Years - 75 Years | Blaze Bioscience Inc. | |
| Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients | NCT03815474 | Sarcoma, Soft T... | anlotinib | 18 Years - | Liaoning Tumor Hospital & Institute | |
| Trabectedin Maintenance Post 1st-line in STS | NCT02929394 | Sarcoma, Soft T... | Trabectedin | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas | NCT00134641 | Sarcoma, Soft T... | gemcitabine vinorelbine | 18 Years - | Dana-Farber Cancer Institute | |
| Metabolic Characteristics of Sarcoma In Vivo Using HP 13-C Magnetic Resonance Spectroscopic Imaging (MRSI) | NCT03759704 | Sarcoma, Soft T... | Hyperpolarized ... | 18 Years - 100 Years | University of Texas Southwestern Medical Center | |
| The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma | NCT04356872 | Sarcoma, Soft T... | Sintilimab Doxorubicin Hyd... Ifosfamide | 18 Years - 75 Years | Fudan University | |
| Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS | NCT01995981 | Sarcoma, Soft T... | Pazopanib | 18 Years - | Radboud University Medical Center | |
| Sunitinib in Certain Subtypes of Soft Tissue Sarcomas | NCT00859456 | Sarcoma, Soft T... | Sunitinib | 18 Years - | Columbia University | |
| Metabolic Characteristics of Sarcoma In Vivo Using HP 13-C Magnetic Resonance Spectroscopic Imaging (MRSI) | NCT03759704 | Sarcoma, Soft T... | Hyperpolarized ... | 18 Years - 100 Years | University of Texas Southwestern Medical Center | |
| Efficacy and Safety Evaluation of Pegamotecan (PEG-camptothecin) in Advanced or Metastatic Soft Tissue Sarcoma | NCT00079950 | Sarcoma, Soft T... | Pegamotecan | 18 Years - | Enzon Pharmaceuticals, Inc. | |
| Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma | NCT00297258 | Sarcoma, Soft T... | pazopanib | 21 Years - | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
